Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This Phase 3 trial tests whether adding anlotinib (a daily pill) to standard chemotherapy can help people with a certain type of advanced colorectal cancer live longer without the disease getting worse. About 748 participants with RAS/BRAF wild-type cancer that has spread will re…

This phase 3 trial tests whether adding an experimental drug (TQB3616) to standard hormone therapy (fulvestrant) can delay cancer growth in people with HR-positive, HER2-negative advanced breast cancer. About 432 participants will receive either the combination or a placebo plus …

This Phase 2 trial tests whether adding TQ-A3334 tablets to standard nucleoside analog therapy can better control chronic hepatitis B. 116 adults with the infection will receive either TQ-A3334 or a placebo, plus standard antivirals. The main goal is to see if the combination low…

This study tests a new drug called TQB3616 combined with standard hormone therapy to see if it can stop breast cancer from returning in women with HR-positive, HER2-negative breast cancer. About 1,946 women who have had surgery will receive either the new drug or a placebo, plus …

This study tests an experimental pill, TQB3454, against a placebo in 165 people with advanced bile duct cancer that has a specific IDH1 gene mutation. The goal is to see if the drug helps people live longer. Participants are randomly assigned to get the drug or a placebo, and nei…

This study tests an experimental tablet called TQ05105 in 45 adults with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't improved with steroids. cGVHD is a condition where donor immune cells attack the recipient's body after a stem cell transplant. The go…

This phase 2 study tests a new drug (TQB3616) combined with hormone therapy for people with a common type of breast cancer (HR-positive, HER2-negative) that has returned or spread and no longer responds to a standard class of drugs called CDK4/6 inhibitors. The trial enrolls 33 a…